A detailed history of Susquehanna International Group, LLP transactions in Legend Biotech Corp stock. As of the latest transaction made, Susquehanna International Group, LLP holds 53,431 shares of LEGN stock, worth $2.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
53,431
Previous 59,073 9.55%
Holding current value
$2.28 Million
Previous $2.62 Million 0.5%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$43.55 - $59.88 $245,709 - $337,842
-5,642 Reduced 9.55%
53,431 $2.6 Million
Q2 2024

Aug 15, 2024

BUY
$39.5 - $57.22 $2.33 Million - $3.38 Million
59,073 New
59,073 $2.62 Million
Q4 2023

Feb 14, 2024

BUY
$57.25 - $69.74 $1.15 Million - $1.4 Million
20,135 Added 148.34%
33,709 $2.03 Million
Q3 2023

Nov 14, 2023

BUY
$63.16 - $76.5 $363,043 - $439,722
5,748 Added 73.45%
13,574 $911,000
Q2 2023

Aug 11, 2023

BUY
$46.28 - $75.01 $362,187 - $587,028
7,826 New
7,826 $540,000
Q4 2022

Feb 14, 2023

BUY
$38.8 - $55.46 $2.15 Million - $3.08 Million
55,532 New
55,532 $2.77 Million
Q1 2022

May 16, 2022

SELL
$31.02 - $48.18 $208,361 - $323,625
-6,717 Reduced 20.57%
25,930 $942,000
Q4 2021

Feb 14, 2022

SELL
$41.14 - $56.98 $973,454 - $1.35 Million
-23,662 Reduced 42.02%
32,647 $1.52 Million
Q2 2021

Aug 11, 2021

BUY
$25.8 - $41.09 $1.26 Million - $2.01 Million
48,823 Added 652.19%
56,309 $2.31 Million
Q1 2021

May 17, 2021

BUY
$23.55 - $32.4 $176,295 - $242,546
7,486 New
7,486 $217,000

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $7.13B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.